Medical robotics developer Robocath has raised €4.7m through a new round of fundraising to market its latest robotic platform called R-one for cardiovascular indications.
Led by M Capital and Normandie Participations, the round also involved Robocath’s past investors, Go Capital and NCI.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In 2013 and 2015, the firm raised €1.8m, to which €1.6m of public aid was added by other investors such as Bpifrance.
Designed to minimise exposure to X-rays, R-one is currently under manufacturing and in the process of securing CE mark.
Robocath chairman and founder Philippe Bencteux said: “The whole team and I would like to thank our historical shareholders, Go Capital and NCI, for their renewed support, and our bank partners BNP Paribas and La Caisse d’Epargne, and our new institutional shareholders for their strong buy-in to our plans.
“This new funding will help us to achieve a decisive milestone in our development strategy. R-one is currently the only robotic assistance platform for interventional cardiology developed in Europe.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We plan to build on this technological edge to enter the European market next year.”
The fully integrated robotics platform is claimed to enable remote management of instruments using a control panel placed adjacent to the operating table.
The new system is based on the R-grasp technology, which reproduces exact hand gestures such as rotation and simultaneous movement, and SecurAccess that offers stability and security during a medical procedure.
While R-one will be launched in Europe next year, it is expected to be introduced in the US in 2019.
